Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | MMP2 | P08253 | 5/20 | 0.41 |
| ▸ | ANPEP | P15144 | 4/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10283713 | 1.00 | ATM (0.71) | ATMMMP2ANPEPCTSKPEPD | |
| SCHEMBL26980896 | 0.85 | ATM (0.52) | ATMCTSKPEPDCTSS | |
| SCHEMBL16349656 | 0.85 | ATM (0.52) | ATMMMP2ANPEPCTSKPEPD | |
| SCHEMBL26980895 | 0.85 | ATM (0.52) | ATMCTSKPEPDCTSS | |
| SCHEMBL6126706 | 0.85 | ATM (0.52) | ATMCTSKPEPDCTSS | |
| SCHEMBL26118721 | 0.85 | ATM (0.52) | ATMCTSKPEPDCTSS | |
| SCHEMBL16300600 | 0.85 | ATM (0.52) | ATMMMP2ANPEPCTSKPEPD | |
| SCHEMBL5087041 | 0.85 | ATM (0.52) | ATMCTSKPEPDCTSS | |
| SCHEMBL16300591 | 0.85 | ATM (0.52) | ATMMMP2ANPEPCTSKPEPD | |
| SCHEMBL12161943 | 0.85 | ATM (0.52) | ATMMMP2ANPEPCTSKPEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20150147309-A1 | ALLOSTERIC CHAPERONES AND USES THEREOF | CONSIGLIO NAZIONALE DELLE RICERCHE (IT) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | ATM 4395/4885MMP2 1235/4885ANPEP 2890/4885 |
| US-20150147309-A1 | ALLOSTERIC CHAPERONES AND USES THEREOF | GAA, GBA3, GBA1 | ATM 3834/4885MMP2 2254/4885ANPEP 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.